Condition: Biliary Tract Cancer · Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group
The objective of this study is to identify prognosis and predictive markers of response to treatments (surgery, chemotherapy, targeted therapy,loco-regional treatments ) in patients with bile duct cancer. The effectiveness and tolerance of these treatments in current practice will also be evaluated.
This description comes directly from the study's public registry record.
Cindy Neuzillet, Dr · +33 (0)1 47 11 15 15 · cindy.neuzillet@curie.fr
Marie-Line Garcia, Dr · +33 (0)1 40 29 85 00 · marie-line.garcia-larnicol@gercor.com.fr
Always discuss trial participation with your own doctor first.
| CHU Hôpital Sud Amiens | Amiens, France | Recruiting |
| CHU Angers | Angers, France | Recruiting |
| CHU Besançon | Besançon, France | Recruiting |
| Hôpital Avicenne | Bobigny, France | Recruiting |
| CHU - Henri Mondor | Créteil, France | Recruiting |
| CHU Dijon | Dijon, France | Recruiting |
| CHU Grenoble | Grenoble, France | Recruiting |
| CHU Lille | Lille, France | Recruiting |
| Centre Léon Bérard | Lyon, France | Recruiting |
| Hôpital Croix Rousse | Lyon, France | Recruiting |
| Hôpital Edouard Herriot | Lyon, France | Recruiting |
| Hôpital Privé Jean Mermoz | Lyon, France | Recruiting |
+ 20 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04935853